|
|
| |
| Articles
by
Nadia Mushtaq |
Total Records (
2 ) for
Nadia Mushtaq |
|
 |
| |
|
| |
Musarat Shaheen
,
Rahmat Ali Khan
,
Mushtaq Ahmed
,
Nadia Mushtaq
and
Nisar Khan
|
| |
Background and Objective: Quercus dilatata is traditionally used for the treatment of various human diseases. The present study was conducted for the determination of in vivo anti-diabetic activity and diabetes complications preventive effect of the Quercus dilatata. Methodology: The methanol extract of Quercus dilatata (200 and 400 mg kg–1; orally) was administered in alloxan induced (150 mg kg–1; intraperitoneally) diabetic rats. Glibenclamide (10 mg kg–1 day–1 orally) was used as a standard drug. Diabetic rats boosted the levels of blood glucose, serum lipids (triglycerides, cholesterol, low density lipoprotein and serum high density lipoprotein levels), liver enzymes (serum alanine transaminase (ALT), alkaline phosphatase (ALP) and total bilirubin), serum urea, creatinine and total protein. Results: After 21 days of treatment, the plant extract at a dose of 200 and 400 mg kg–1 day–1 significantly reduced the elevated blood glucose level in diabetic rats by 114.975 and 111.520%, respectively. Extracts of Quercus dilatata (both doses) proved to have anti-diabetic activity by decreasing the elevated level of plasma blood glucose, with subsequent increase in body weight. Extracts of Quercus dilatata (both doses) also proved to have lipids, hepatic and renal protective activity by reducing the elevated level of enzymes and other biochemical markers. Extract at a dose of 200 mg kg–1 revealed highly significant (p<0.05)results as compared to 400 mg kg–1 dose. Conclusion: On the basis of the results it is concluded that Quercus dilatata extract can be used to treat diabetes, kidney and liver disorders and serum lipids related abnormality. |
|
| |
|
| |
Wasim Ahmad
,
Mushtaq Ahmad
,
Rahmat Ali Khan
,
Nadia Mushtaq
,
Jean Paul Kamdem
and
Joao Batista Teixeira da Rocha
|
| |
Background and Objective: Ischemia is a stern decline or absolute obstruction in blood, flowing to various parts of the body. This pathophysiological episode causes cerebral mutilation, a protuberant feature of stroke, which is the 3rd leading cause of demise after cancer and heart attack globally. The principal objective of this work was to understand the sights of neuroprotection provided by M. Officinalis against OGD-R in rat’s brain cortex slices. Materials and Methods: Mitochondrial viability assays were performed via the colorimetric 3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. After 2 h of oxygen and glucose deprivation (OGD) followed by 1 h of reperfusion, only viable slices showed the ability to trim down MTT into a purple "Formazan" product that was soluble in dimethyl sulfoxide (DMSO). Absorbance was measured at 570 and 630 nm and the net absorbance (A570-A630) was taken as an index of cell viability. Results: The results of the present investigation demonstrated that oxygen-glucose deprivation (OGD) followed by re-oxygenation led to cell damage/death via an amplifying ROS/free radicals production in rat’s brain cortex slices compared with control after 2 h OGD followed by 1h reperfusion. Melissa officinalis at a concentration of 40 μg mL–1 displayed potential role in neuro-protection against OGD, followed by re-oxygenation in mitochondrial viability assays in vitro. In addition, Melissa officinalis declined or slow down the production of free radicals in the supernatant and slices homogenate of cortex at the end of 2 h OGD followed by 1 h reperfusion. Furthermore, higher concentrations of Melissa officinalis slightly showed neurotoxicity for cortex slices which might be attributed to its pro-oxidant outcome. Conclusion: The results obtained during this study offer evidence for neuroprotective properties of M. officinalis against in vitro ischemia in rat’s cortex slices. Melissa officinalis could be considered as a therapeutic agent in the prevention of neuronal cell death in Ischemia induced by oxygen and glucose deprivation of cortex slices, strengthening further investigations to define the actual component for its use in human. Furthermore, in vivo ischemic models are now in progress to confirm and better characterize its neuroprotection. |
|
|
|
|
| |
|
